0001104659-23-085942.txt : 20230801 0001104659-23-085942.hdr.sgml : 20230801 20230731201450 ACCESSION NUMBER: 0001104659-23-085942 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230727 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Assertio Holdings, Inc. CENTRAL INDEX KEY: 0001808665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850598378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39294 FILM NUMBER: 231129169 BUSINESS ADDRESS: STREET 1: 100 S. SAUNDERS ROAD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: (224) 419-7106 MAIL ADDRESS: STREET 1: 100 S. SAUNDERS ROAD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 8-K 1 tm2322207d1_8k.htm FORM 8-K
0001808665 false 0001808665 2023-07-27 2023-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

July 27, 2023

Date of Report (Date of earliest event reported)

 

 

 

ASSERTIO HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39294   85-0598378
(State or Other Jurisdiction of
Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification Number)

 

100 South Saunders Rd., Suite 300

Lake Forest, IL 60045

(Address of principal executive offices) (Zip Code)

 

(224) 419-7106

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value ASRT The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Introductory Note

 

As previously announced, on April 24, 2023, Assertio Holdings, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Spade Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Spectrum Pharmaceuticals, Inc., a Delaware corporation (“Spectrum”).

 

On July 27, 2023, the Company held a virtual special meeting of its stockholders (the “Special Meeting”) to vote on the proposals identified in the Company’s definitive joint proxy statement/prospectus initially filed with the Securities and Exchange Commission on June 2, 2023, and declared effective on June 15, 2023, and mailed to the Company’s stockholders on June 15, 2023. The stockholders approved all proposals.

 

On July 31, 2023, the Company completed the previously announced acquisition of Spectrum pursuant to the Merger Agreement. Under the Merger Agreement, Merger Sub merged with and into Spectrum (the “Merger”), with Spectrum surviving such Merger as a wholly owned subsidiary of the Company. The Merger became effective on July 31, 2023 upon the filing of the Certificate of Merger with the Secretary of the State of Delaware (the time of such filing, the “Effective Time”). Additionally, on July 31, 2023, in connection with the Merger Agreement, Assertio and Computershare Trust Company, N.A., as rights agent, entered into a contingent value right (“CVR”) agreement, pursuant to which each holder of (i) common stock, par value $0.001 per share, of Spectrum (“Spectrum Common Stock”) (other than holders of Common Stock (x) that was canceled in accordance with the terms of the Merger Agreement or (y) who properly exercised appraisal rights under Delaware law) and (ii) Spectrum restricted stock units ("Spectrum RSUs"), certain stock appreciation rights (“Spectrum SARs”), certain options to purchase Spectrum Common Stock (“Spectrum Stock Options”) and warrants to purchase Spectrum Common Stock (“Spectrum Warrants”), were entitled to one CVR. Each CVR entitled the holder thereof to receive contingent payments of cash or common stock, par value $0.0001 per share, of the Company (“Company Common Stock”) upon the achievement of certain milestones.

 

The following events took place in connection with the completion of the Merger.

 

Item 2.01 Completion of Acquisition or Disposition of Assets

 

The information included in the Introductory Note is incorporated herein by reference into this Item 2.01.

 

Merger Consideration

 

Under the Merger Agreement, at the Effective Time, each share of Spectrum Common Stock issued and outstanding immediately prior to the Effective Time (other than (i) treasury shares, (ii) any shares of Spectrum Common Stock held directly by the Company or Merger Sub and (iii) shares of Spectrum Common Stock held by any holder who properly demanded appraisal of such shares in compliance with Section 262 of the Delaware General Corporation Law) was converted into the right to receive (A) 0.1783 (the “Exchange Ratio”) of a fully paid and non-assessable share of Company Common Stock and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding (the “Upfront Consideration”), and (B) one CVR representing a contractual right to receive future conditional payments worth up to an aggregate maximum amount of $0.20, settleable in cash, additional shares of common stock of the Company or a combination of cash and additional shares of common stock of the Company, at the Company’s sole discretion (and subject, in each case, to deduction for any required withholding taxes), upon the achievement of certain sales milestones related to Spectrum’s product ROLVEDON® (collectively, with the Upfront Consideration, the “Merger Consideration”).

 

At the Effective Time, each Spectrum Stock Option (other than an option under Spectrum’s employee stock purchase plan) to purchase Spectrum Common Stock granted under any of Spectrum’s equity incentive plans, that was outstanding immediately prior to the Effective Time became vested (if unvested) and was automatically and without any required action on the part of the holder or Spectrum, cancelled and treated as follows:

 

●With respect to any Spectrum Stock Options with an exercise price per share less than the value of the Upfront Consideration, such Spectrum Stock Options were converted into the right to receive (i) a number of shares of Company Common Stock, subject to certain exceptions with respect to fractional shares and any applicable withholdings, that is equal to the quotient of (A) the product of (x) the total number of shares of Spectrum Common Stock underlying the Spectrum Stock Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Spectrum Stock Option, divided by (B) the average of the daily volume-weighted average price per share of Company Common Stock calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (ii) a number of CVRs equal to the number of shares of Spectrum Common Stock underlying such Spectrum Stock Option.

 

 

 

 

●With respect to any Spectrum Stock Options with an exercise per share equal to or greater than the value of the Upfront Consideration and less than the sum of the Upfront Consideration and the maximum amount payable under a CVR (each, a “Contingent In-the-Money Stock Option”), such Contingent In-the-Money Stock Options were converted into the right to receive a number of CVRs equal the number of shares of Spectrum Common Stock underlying such Spectrum Stock Option; provided, however, that the payment, if any, under each CVR was reduced by the amount by which the exercise price per share exceeds the value of the Upfront Consideration; provided, further that, for the avoidance of doubt, such Contingent In-the-Money Stock Option shall not entitle the holder thereof to receive any shares of Company Common Stock, cash or other consideration in connection with the Effective Time.

 

● With respect to any Spectrum Stock Options with an exercise price per share equal to or greater than the value of the Merger Consideration (each, an “Underwater Spectrum Stock Option”), the holder of such Underwater Spectrum Stock Options received no consideration and, effective as of immediately prior to the Effective Time, shall have no further rights thereto.

 

At the Effective Time, each Spectrum RSU with respect to Spectrum Common Stock granted under Spectrum’s equity incentive plans, whether vested or unvested, that was outstanding immediately prior to the Effective Time became fully vested, and the holder of such Spectrum RSUs automatically and without any required action on the part of the holder thereof or Spectrum received the Merger Consideration.

 

At the Effective Time, each unvested restricted Spectrum Common Stock granted under Spectrum’s equity incentive plans that was outstanding immediately prior to the Effective Time automatically and without any required action on the part of the holder thereof or Spectrum, became fully vested and is now treated like all other shares of Spectrum Common Stock.

 

At the Effective Time, each Spectrum SAR granted under Spectrum equity incentive plans that was outstanding as of immediately prior to the Effective Time, became vested (if unvested) and was automatically, and without any required action on the part of the holder or Spectrum, cancelled and treated as follows:

 

●With respect to any Spectrum SARs with an exercise price per share less than the value of the Upfront Consideration (each such Spectrum SAR, an “In-the-Money SAR”), such In-the-Money SARs were converted into the right to receive (i) a number of shares of Company Common Stock, subject to certain terms with respect to fractional shares and any required withholding of taxes pursuant as described further in the Merger Agreement, that was equal to the quotient of (A) the product of (x) the total number of shares of Spectrum Common Stock underlying the Spectrum SAR multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Spectrum SAR, divided by (B) the average of the daily volume-weighted average price per share of Company Common Stock calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (ii) a number of CVRs equal to the number of shares of Spectrum Common Stock underlying such Spectrum SAR.

 

●With respect to any Spectrum SARs with an exercise price per share equal to or greater than the value of the Upfront Consideration and less than the sum of the Upfront Consideration and the maximum amount payable under a CVR (each, a “Contingent In-the-Money SAR”), such Contingent In-the-Money SARs were converted into the right to receive a number of CVRs equal the number of shares of Spectrum Common Stock underlying such Spectrum SAR; provided, however, that the payment, if any, under each CVR shall was reduced by the amount by which the exercise price per share exceeded the value of the Upfront Consideration; provided, further that, for the avoidance of doubt, such Contingent In-the-Money SAR shall not entitle the holder thereof to receive any shares of Company Common Stock, cash or other consideration in connection with the Effective Time.

 

●With respect to any Spectrum SAR with an exercise price per share equal to or greater than the value of the Merger Consideration (each, an “Underwater Spectrum SAR”), the holder of such Underwater Spectrum SARs received no consideration and, effective as of immediately prior to the Effective Time, shall have no further rights thereto.

 

At the Effective Time, upon the election of the holder of each Spectrum Warrant, under that certain Warrant to Purchase Stock, dated as of September 21, 2022, by and between Spectrum and SLR Investment Corp., a Maryland corporation, that was outstanding immediately prior to the Effective Time were cancelled and, in exchange therefor, Spectrum shall pay to each former holder of any such cancelled Spectrum Warrant as soon as practicable following the Effective Time (i) a number of shares of Company Common Stock equal to the (A) product of (x) the excess of $1.10 over the exercise price per Spectrum Common Stock under such Spectrum Warrant, and (y) the number of shares of Spectrum Common Stock subject to such Spectrum Warrant, multiplied by (B) the Exchange Ratio, and (ii) one CVR for Spectrum Common Stock underlying such Spectrum Warrant, in each case, without interest, and subject to deduction for any required withholding of taxes.

 

 

 

 

The foregoing description of the Merger Agreement and the Merger does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, a copy of which was attached as Exhibit 2.1 of the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 25, 2023, the terms of which are incorporated herein by reference.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

Appointment of Jeffrey Vacirca, MD, FACP, to the Company’s Board of Directors

 

As of the Effective Time and in accordance with the Merger Agreement, the Company’s Board of Directors (the “Board”) voted to increase the size of the Board from five directors to six directors and appointed Jeffrey Vacirca, MD, FACP to the Board. The Board has determined that Mr. Vacirca qualifies as an independent director under the corporate governance standards of The Nasdaq Stock Market and the applicable rules adopted by the U.S. Securities and Exchange Commission (the “SEC”).

 

The compensation of Mr. Vacirca for his service as a non-employee director will be consistent with that of the Company’s other non-employee directors, which is described in the Company’s definitive proxy statement filed on April 3, 2023 with the SEC.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The information included in the Introductory Note is incorporated herein by reference into this Item 5.07.

 

As of June 13, 2023, the record date for the Special Meeting, there were 56,512,962 shares of the Company’s common stock issued and outstanding. At the Special Meeting, a total of 32,883,168 shares of the Company’s common stock were present virtually or by proxy, representing 58.187% of the total number of shares outstanding and entitled to vote at the Special Meeting and a quorum for all matters before the stockholders as required by the Company’s Amended and Restated Bylaws, as amended.

 

The number of votes cast for and against, as well as abstention votes and broker non-votes, as applicable, with respect to each proposal presented at the Special Meeting was as follows:

 

Proposal No. 1 - Approval of the Share Issuance.

 

The stockholders approved the issuance of shares of the Company’s common stock to Spectrum stockholders in connection with the Merger (including such shares issued as payment under the non-tradeable contingent value rights) (the “Assertio share issuance proposal”) as follows:

 

FOR  AGAINST  ABSTAIN
28,898,637  3,912,936  71,595

 

Proposal No. 2 - Adjournment of the Assertio Special Meeting.

 

The stockholders approved the proposal to adjourn the Special Meeting to solicit additional proxies if there are insufficient votes to approve the Assertio share issuance proposal or to ensure that any supplement or amendment to the joint proxy statement/prospectus is timely provided to Assertio stockholders as follows:

 

 

 

 

FOR  AGAINST  ABSTAIN
28,787,617  4,008,573  86,978

 

However, because Proposal No. 1 to approve the Assertio share issuance proposal was approved, the adjournment of the Special Meeting was not necessary to continue to solicit additional proxies and, accordingly, the Special Meeting was not adjourned.

 

Item 7.01 Regulation FD Disclosure

 

On July 31, 2023, the Company issued a press release announcing the completion of the Merger, described above in Item 2.01, and the appointment of Jeffrey Vacirca, MD, FACP, described above in Item 5.02. A copy of the press release is furnished hereto as Exhibit 99.2. The information in this Item 7.01, including Exhibit 99.2 attached hereto, is furnished pursuant to Item 7.01 of this Current Report on Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended.

 

Item 8.01 Other Events.

 

On July 27, 2023, the Company and Spectrum announced in a joint press release the voting results relating to the Special Meeting, and the special meeting of the stockholders of Spectrum approving the Merger and the transactions contemplated thereby. A copy of the joint press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits

 

(a)Financial Statements of Business Acquired

 

As permitted by Item 9.01(a)(3) of Form 8-K, the financial statements required by this Item will be filed by amendment to this Current Report on Form 8-K within 71 days following the date on which this Current Report on Form 8-K is required to be filed.

 

(b)Pro Forma Financial Information

 

As permitted by Item 9.01(a)(3) of Form 8-K, the pro forma financial statements required by this Item will be filed by amendment to this Current Report on Form 8-K within 71 days following the date on which this Current Report on Form 8-K is required to be filed.

 

(d)Exhibits

 

Exhibit
Number

 

Description

 

2.1 Agreement and Plan of Merger, dated as of April 24, 2023, by and among Spectrum Pharmaceuticals, Inc., Assertio Holdings, Inc. and Spade Merger Sub 1, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed on April 25, 2023).
99.1 Joint Press Release Announcing Meeting Results, dated July 27, 2023.
99.2 Press Release Announcing Transaction Close and Board Appointment, dated July 31, 2023.
104 Cover Page Interactive Data File (the Cover Page XBRL tags are embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 31, 2023 ASSERTIO HOLDINGS, INC.
     
  By: /s/ Daniel A. Peisert
  Name: Daniel A. Peisert
  Title: President and Chief Executive Officer

 

 

 

 EX-99.1 2 tm2322207d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Assertio Holdings, Inc Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals

 

Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction

 

Transaction Expected to be Significantly Accretive to Assertio in 2024

 

LAKE FOREST, Ill., and BOSTON -- July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights (CVR) transaction.

 

“We are pleased to announce the positive voting results of each meeting and look forward to closing the transaction in the coming days,” said Dan Peisert, President and Chief Executive Officer of Assertio. “We believe this transaction provides extensive new growth opportunities and will be accretive to our stockholders in 2024. We plan to provide updated guidance on our second quarter results call, scheduled for August 3.”

 

About Assertio

 

Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more about Assertio, visit www.assertiotx.com.

 

About Spectrum

 

Spectrum is a commercial stage biopharmaceutical company, with a strategy of acquiring, developing, and commercializing novel and targeted oncology therapies. We have an in-house clinical development organization with regulatory and data management capabilities, in addition to commercial infrastructure and a field based sales force for our marketed product, ROLVEDON® (eflapegrastim-xnst) Injection. For additional information on Spectrum please visit www.sppirx.com.

 

Assertio Forward Looking Statements

 

Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio's and Spectrum’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, the preliminary, unaudited financial results included in this press release, future events or the future performance or operations of Assertio and Spectrum, including our ability to realize the benefits from our operating model, successfully acquire and integrate new assets and explore new business development initiatives. All statements other than historical facts may be forward-looking statements and can be identified by words such as "anticipate," "believe," "could," "design," "estimate," "expect," "forecast," "goal," "guidance," "imply," "intend," "may", "objective," "opportunity," "outlook," "plan," "position," "potential," "predict," "project," "prospective," "pursue," "seek," "should," "strategy," "target," "would," "will," "aim" or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio and Spectrum, including the risks described in Assertio's and Spectrum’s respective Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") and in other filings each of Assertio and Spectrum makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio and Spectrum may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law.

 

 

 

 

Assertio Investor Contact

 

Matt Kreps

Darrow Associates

M: 214-597-8200

mkreps@darrowir.com

 

Spectrum Investor Contact

 

Nora Brennan

Chief Financial Officer

M: 949-788-6700

InvestorRelations@sppirx.com

 

Lisa Wilson

In-Site Communications, Inc.

212-452-2793

lwilson@insitecony.com

 

 

 EX-99.2 3 tm2322207d1_ex99-2.htm EXHIBIT 99.2

 

Exhibit 99.2

 

 

Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

 

Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products

 

Transaction Expected to be Significantly Accretive to Assertio in 2024

 

LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology.

 

Assertio intends to provide updated guidance for the combined business as part of its second quarter results call on August 3.

 

“We are pleased to close the acquisition of Spectrum and its ROLVEDON® (eflapegrastim-xnst) Injection asset, as well as bring onboard an incredible commercial team with proven successful results,” said Dan Peisert, President and Chief Executive Officer of Assertio. “We believe this combination will expand and diversify Assertio’s revenue base, complement our digital non-personal marketing capabilities and enhance our IP portfolio as we continue to scale our platform and its capabilities. We look forward to building on the successful early results in the ROLVEDON® (eflapegrastim-xnst) Injection launch for the remainder of 2023, driving the business toward our goal of accretive contribution to our Adjusted EPS and operating cash flow in 2024.”

 

As part of the closing, Assertio also announced the appointment of Jeffrey Vacirca, MD, FACP, to its Board of Directors. Vacirca qualifies as an independent director under Nasdaq rules.

 

Jeffrey Vacirca, MD, FACP, is a renowned cancer physician and visionary leader with extensive experience and commitment to community oncology. Dr. Vacirca assumed the role of CEO and Chairman of the Board of New York Cancer & Blood Specialists (NYCBS) in 2008. After two years, the practice emerged as a stronger unified group of physicians dedicated to reinventing themselves as the premier cancer care deliverers of New York.

 

He has led NYCBS through an unparalleled period of transformation and incredible growth to become the leading oncology practice that now sees nearly a million patients a year throughout more than 30 oncology locations and 35 hospital affiliations.

 

Dr. Vacirca takes action against key billings, including abuse of pharmacy benefit managers (PBMs) and sequester cuts. He formed the Conquering Cancer PAC, which advocates for cancer patients and strives to ensure access and availability for all patients no matter where they live.

 

 

 

He also serves on the board of directors of Annexus Health, Spectrum Pharmaceuticals, OneOncology, and the American Red Cross of Greater New York. Most of his roles in these remarkable companies focus on legislative advocacy for the cost of cancer care and access. Dr. Vacirca is the immediate past president of the Community Oncology Alliance (COA) and continues to be a member of their executive committee. He serves on the board of Scientific Advisory for Caris Life Sciences, and is president and co-founder of the National Translational Research Group. He has also been part of early funding for remarkable companies, including Cedar, Thyme Care, and Sherpa Health. Dr. Vacirca co-founded Odonate Therapeutics in 2016.

 

Dr. Vacirca is the founder and Chairman of the Board of Directors of the New York Cancer Foundation, which provides financial assistance to patients undergoing treatment for cancer. In addition, Dr. Vacirca is the Medical Director of Oncology Network Development at Mount Sinai Health Network and Lab Director for the Long Island Association for AIDS Care (LIAAC).

 

Dr. Vacirca was honored as Humanitarian of the Year by the American Red Cross and received its Corporate Leadership Award on behalf of NYCBS. He was awarded the Red Door Award for Leadership and Cancer Advocacy by the Red Door Community and received the Founders Medalist by The Brooklyn Hospital. Dr. Vacirca also received the Theodore Roosevelt Award for outstanding dedication to patient care and was named Newsday's Top Doctor. He was also honored for his role in enabling the Long Island Association for AIDS Care staff to bring state-of-the-art HIV testing to New York.

 

About Assertio

 

Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more about Assertio, visit www.assertiotx.com.

 

Assertio Forward Looking Statements

 

Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio's current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, the preliminary, unaudited financial results included in this press release, future events or the future performance or operations of Assertio, including our ability to realize the benefits from our operating model, successfully acquire and integrate new assets and explore new business development initiatives. All statements other than historical facts may be forward-looking statements and can be identified by words such as "anticipate," "believe," "could," "design," "estimate," "expect," "forecast," "goal," "guidance," "imply," "intend," "may", "objective," "opportunity," "outlook," "plan," "position," "potential," "predict," "project," "prospective," "pursue," "seek," "should," "strategy," "target," "would," "will," "aim" or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio, including the risks described in Assertio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") and in other filings Assertio makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law.

 

 

 

Assertio Investor Contact

 

Matt Kreps

Darrow Associates

M: 214-597-8200

mkreps@darrowir.com

 

 

 EX-101.SCH 4 asrt-20230727.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 asrt-20230727_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 asrt-20230727_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2322207d1_ex99-1img001.jpg GRAPHIC begin 644 tm2322207d1_ex99-1img001.jpg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end GRAPHIC 8 tm2322207d1_ex99-2img03.jpg GRAPHIC begin 644 tm2322207d1_ex99-2img03.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jul. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 27, 2023
Entity File Number 001-39294
Entity Registrant Name ASSERTIO HOLDINGS, INC.
Entity Central Index Key 0001808665
Entity Tax Identification Number 85-0598378
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 South Saunders Rd.
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Lake Forest
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60045
City Area Code 224
Local Phone Number 419-7106
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol ASRT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 tm2322207d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001808665 2023-07-27 2023-07-27 iso4217:USD shares iso4217:USD shares 0001808665 false 8-K 2023-07-27 ASSERTIO HOLDINGS, INC. DE 001-39294 85-0598378 100 South Saunders Rd. Suite 300 Lake Forest IL 60045 224 419-7106 false false false false Common Stock, $0.0001 par value ASRT NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://assertiotx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2322207d1_8k.htm asrt-20230727.xsd asrt-20230727_lab.xml asrt-20230727_pre.xml tm2322207d1_ex99-1.htm tm2322207d1_ex99-2.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2322207d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2322207d1_8k.htm" ] }, "labelLink": { "local": [ "asrt-20230727_lab.xml" ] }, "presentationLink": { "local": [ "asrt-20230727_pre.xml" ] }, "schema": { "local": [ "asrt-20230727.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "asrt", "nsuri": "http://assertiotx.com/20230727", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2322207d1_8k.htm", "contextRef": "AsOf2023-07-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://assertiotx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2322207d1_8k.htm", "contextRef": "AsOf2023-07-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://assertiotx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001104659-23-085942-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-085942-xbrl.zip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end